SG11202001115TA - Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody - Google Patents
Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibodyInfo
- Publication number
- SG11202001115TA SG11202001115TA SG11202001115TA SG11202001115TA SG11202001115TA SG 11202001115T A SG11202001115T A SG 11202001115TA SG 11202001115T A SG11202001115T A SG 11202001115TA SG 11202001115T A SG11202001115T A SG 11202001115TA SG 11202001115T A SG11202001115T A SG 11202001115TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- combination therapy
- treating cancer
- intravenous administration
- recombinant mva
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187824 | 2017-08-24 | ||
| PCT/EP2018/072789 WO2019038388A1 (en) | 2017-08-24 | 2018-08-23 | POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001115TA true SG11202001115TA (en) | 2020-03-30 |
Family
ID=59702586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001115TA SG11202001115TA (en) | 2017-08-24 | 2018-08-23 | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273211B2 (https=) |
| EP (1) | EP3691675A1 (https=) |
| JP (1) | JP7202362B2 (https=) |
| KR (1) | KR102754876B1 (https=) |
| CN (1) | CN111050790B (https=) |
| AU (1) | AU2018320417B2 (https=) |
| BR (1) | BR112020003669A2 (https=) |
| CA (1) | CA3073310A1 (https=) |
| IL (1) | IL272546B2 (https=) |
| MX (1) | MX2020001856A (https=) |
| SG (1) | SG11202001115TA (https=) |
| WO (1) | WO2019038388A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| US20230190922A1 (en) * | 2019-11-20 | 2023-06-22 | Bavarian Nordic A/S | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer |
| IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| CA3183774A1 (en) * | 2020-06-26 | 2021-12-30 | National Breast Cancer Coalition | Breast cancer vaccine |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022192268A1 (en) * | 2021-03-10 | 2022-09-15 | University Of Iowa Research Foundation | Methods of enhancing antibody therapies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
| EP1865065A1 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| CN101173282B (zh) * | 2003-07-21 | 2011-04-06 | P.安杰莱蒂分子生物学研究所 | 编码人表皮生长因子2/neu抗原的合成基因及其用途 |
| NZ592082A (en) | 2008-11-27 | 2013-03-28 | Bavarian Nordic As | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| MX2011010977A (es) | 2009-04-17 | 2012-02-29 | Us Health | Composiciones inmunoterapeuticas combinadas contra cancer y metodos. |
| WO2013189611A1 (en) | 2012-06-22 | 2013-12-27 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014037124A1 (en) | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| EP2912183B1 (en) | 2012-10-28 | 2020-05-06 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| AU2014347004B2 (en) | 2013-11-05 | 2019-08-08 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor |
| UA127337C2 (uk) * | 2013-11-28 | 2023-07-26 | Баваріан Нордік А/С | Рекомбінантний поксвірус для індукції посиленої імунної відповіді та його застосування |
| KR102499737B1 (ko) * | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| JP2017530114A (ja) * | 2014-09-26 | 2017-10-12 | バヴァリアン・ノルディック・アクティーゼルスカブ | フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物 |
| ES2901468T3 (es) | 2015-07-31 | 2022-03-22 | Bavarian Nordic As | Promotores para mejorar la expresión en poxvirus |
| CA3119503A1 (en) * | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| IL293012A (en) * | 2019-11-20 | 2022-07-01 | Bavarian Nordic As | Medicinal uses of 4-1bbl modified ankara virus vaccinia ((recombinant mva |
| WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
-
2018
- 2018-08-23 CN CN201880054776.8A patent/CN111050790B/zh active Active
- 2018-08-23 WO PCT/EP2018/072789 patent/WO2019038388A1/en not_active Ceased
- 2018-08-23 IL IL272546A patent/IL272546B2/en unknown
- 2018-08-23 BR BR112020003669-2A patent/BR112020003669A2/pt unknown
- 2018-08-23 CA CA3073310A patent/CA3073310A1/en active Pending
- 2018-08-23 EP EP18756447.1A patent/EP3691675A1/en active Pending
- 2018-08-23 SG SG11202001115TA patent/SG11202001115TA/en unknown
- 2018-08-23 AU AU2018320417A patent/AU2018320417B2/en active Active
- 2018-08-23 JP JP2020511314A patent/JP7202362B2/ja active Active
- 2018-08-23 KR KR1020207005076A patent/KR102754876B1/ko active Active
- 2018-08-23 MX MX2020001856A patent/MX2020001856A/es unknown
- 2018-08-23 US US16/641,236 patent/US11273211B2/en active Active
-
2022
- 2022-03-14 US US17/693,716 patent/US11723964B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11273211B2 (en) | 2022-03-15 |
| AU2018320417A1 (en) | 2020-02-27 |
| WO2019038388A1 (en) | 2019-02-28 |
| IL272546A (en) | 2020-03-31 |
| KR20200044000A (ko) | 2020-04-28 |
| AU2018320417B2 (en) | 2024-11-14 |
| IL272546B1 (en) | 2023-09-01 |
| JP2020531524A (ja) | 2020-11-05 |
| US11723964B2 (en) | 2023-08-15 |
| RU2020111588A3 (https=) | 2022-03-29 |
| IL272546B2 (en) | 2024-01-01 |
| CN111050790A (zh) | 2020-04-21 |
| CN111050790B (zh) | 2024-07-12 |
| US20220249636A1 (en) | 2022-08-11 |
| BR112020003669A2 (pt) | 2020-09-01 |
| JP7202362B2 (ja) | 2023-01-11 |
| RU2020111588A (ru) | 2021-09-24 |
| MX2020001856A (es) | 2020-07-13 |
| CA3073310A1 (en) | 2019-02-28 |
| EP3691675A1 (en) | 2020-08-12 |
| US20200306352A1 (en) | 2020-10-01 |
| KR102754876B1 (ko) | 2025-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272546A (en) | Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody | |
| IL290695A (en) | Combined immunotherapy and cytokine control therapy for cancer treatment | |
| IL297418B1 (en) | Combination immune therapy and cytokine control therapy for cancer treatment | |
| IL261008B1 (en) | Combined immunotherapy and cytokine control therapy for cancer treatment | |
| IL272636A (en) | Drug delivery device with combination assembly and related assembly method | |
| IL283187A (en) | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l | |
| IL248507A0 (en) | Combined therapy for the treatment of cancer with a recombinant focovirus that expresses an antigen and an antagonist or agonist for an immune control molecule | |
| IL258212A (en) | Combination therapy of bromodomain inhibitors and checkpoint blockade | |
| IL267795A (en) | Combined treatment for cancer | |
| IL275550A (en) | Recombinant virus on a region reduced from optimal for a codon pair and its use for cancer treatment | |
| MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
| IL275940A (en) | Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment | |
| MX2023008849A (es) | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. | |
| IL281988A (en) | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist | |
| IL248704A0 (en) | Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2 | |
| IL282007A (en) | Medicine to treat chronic cough | |
| SG11202103141YA (en) | Combination therapy for the treatment of cancer | |
| IL304245A (en) | Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
| IL284162A (en) | Integrated healing for cancer treatment | |
| PL3664770T3 (pl) | Kosmetyk nasycony gazem terapeutycznym i sposoby nasycania | |
| IL288178A (en) | Combined gmci and ddri treatment for cancer | |
| HK40028707A (en) | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody | |
| GB201518170D0 (en) | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |